Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Frodermann, Vanessa ^a,d   Van Duijn, Janine ^a   Van Pel, Melissa ^b   Van Santbrink, Peter J ^a   Bot, Ilze ^a   Kuiper, Johan ^a   De Jager, Saskia C A ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL; AORTA; ATHEROSCLEROSIS; DIET; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; PATHOLOGY; REGULATORY T LYMPHOCYTE;

ANIMALS; AORTA; ATHEROSCLEROSIS; DIET; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MACROPHAGES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; RECEPTORS, LDL; T-LYMPHOCYTES, REGULATORY;

EID: 84944883906     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15559     Document Type: Article

References (59)

1. Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-7 (1999).
2. Bernardo, M. E. & Fibbe, W. E. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 13, 392-402 (2013).
3. Toma, C., Pittenger, M. F., Cahill, K. S., Byrne, B. J. & Kessler, P. D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105, 93-8 (2002).
4. Mangi, A. A. et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 9, 1195-201 (2003).
5. Atsma, D. E., Fibbe, W. E. & Rabelink, T. J. Opportunities and challenges for mesenchymal stem cell-mediated heart repair. Curr. Opin. Lipidol. 18, 645-9 (2007).
6. Barbash, I. M. et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108, 863-8 (2003).
7. Amado, L. C. et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc. Natl. Acad. Sci. USA 102, 11474-9 (2005).
8. Silva, G. V. et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111, 150-6 (2005).
9. Houtgraaf, J. H. et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ. Res. 113, 153-66 (2013).
10. Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8, 726-36 (2008).
11. Dayan, V. et al. Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res. Cardiol. 106, 1299-310 (2011).
12. Németh, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15, 42-9 (2009).
13. Melief, S. M., Geutskens, S. B., Fibbe, W. E. & Roelofs, H. Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica 98, 888-95 (2013).
14. Melief, S. M. et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 31, 1980-91 (2013).
15. Nauta, A. J., Kruisselbrink, A. B., Lurvink, E., Willemze, R. & Fibbe, W. E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 177, 2080-7 (2006).
16. Aggarwal, S. & Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-22 (2005).
17. Beyth, S. et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105, 2214-9 (2005).
18. Bartholomew, A. et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42-8 (2002).
19. Glennie, S., Soeiro, I., Dyson, P. J., Lam, E. W.-F. & Dazzi, F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105, 2821-7 (2005).
20. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685-95 (2005).
21. Weber, C., Zernecke, A. & Libby, P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol. 8, 802-15 (2008).
22. Taghavie-Moghadam, P. L., Butcher, M. J. & Galkina, E. V. The dynamic lives of macrophage and dendritic cell subsets in atherosclerosis. Ann. N. Y. Acad. Sci. 1319, 19-37 (2014).
23. Emeson, E. E., Shen, M. L., Bell, C. G. & Qureshi, A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am. J. Pathol. 149, 675-85 (1996).
24. Frostegård, J. et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145, 33-43 (1999).
25. Zhou, X., Paulsson, G., Stemme, S. & Hansson, G. K. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101, 1717-25 (1998).
26. Voloshyna, I., Littlefield, M. J. & Reiss, A. B. Atherosclerosis and interferon : new insights and therapeutic targets. Trends Cardiovasc. Med. 24, 45-51 (2014).
27. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 11, 723-37 (2011).
28. Chistiakov, D. A., Sobenin, I. A., Orekhov, A. N. & Bobryshev, Y. V. Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects. Front. Physiol. 5, 196 (2014).
29. Foks, A. C., Lichtman, A. H. & Kuiper, J. Treating Atherosclerosis With Regulatory T Cells. Arterioscler. Thromb. Vasc. Biol. (2014), doi: 10. 1161/ATVBAHA. 114. 303568.
30. Reinders, M. E. J. et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl. Med. 2, 107-11 (2013).
31. Zappia, E. et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106, 1755-61 (2005).
32. Augello, A., Tasso, R., Negrini, S. M., Cancedda, R. & Pennesi, G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56, 1175-86 (2007).
33. Fan, H. et al. Pre-treatment with IL-1? enhances the efficacy of MSC transplantation in DSS-induced colitis. Cell. Mol. Immunol. 9, 473-81 (2012).
34. Le Blanc, K. et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579-86 (2008).
35. Weinstock, P. H. et al. Lipoprotein lipase controls fatty acid entry into adipose tissue, but fat mass is preserved by endogenous synthesis in mice deficient in adipose tissue lipoprotein lipase. Proc. Natl. Acad. Sci. USA 94, 10261-6 (1997).
36. Liu, X., Strable, M. S. & Ntambi, J. M. Stearoyl CoA desaturase 1: role in cellular inflammation and stress. Adv. Nutr. 2, 15-22 (2011).
37. Karasawa, T. et al. Sterol regulatory element-binding protein-1 determines plasma remnant lipoproteins and accelerates atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31, 1788-95 (2011).
38. Wang, Z. X. et al. Mesenchymal stem cells alleviate atherosclerosis by elevating number and function of CD4+ CD25+ FOXP3+ regulatory T-cells and inhibiting macrophage foam cell formation. Mol. Cell. Biochem. 400, 163-172 (2014).
39. Akiyama, K. et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 10, 544-55 (2012).
40. Lo, J. C. et al. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 316, 285-8 (2007).
41. Upadhyay, V. & Fu, Y.-X. Lymphotoxin signalling in immune homeostasis and the control of microorganisms. Nat. Rev. Immunol. 13, 270-9 (2013).
42. Gautier, E. L. et al. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation 119, 2367-75 (2009).
43. Habets, K. L. L. et al. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc. Res. 85, 622-30 (2010).
44. Camps, L. et al. Lipoprotein lipase in lungs, spleen, and liver: synthesis and distribution. J. Lipid Res. 32, 1877-88 (1991).
45. Coleman, T. et al. COOH-terminal disruption of lipoprotein lipase in mice is lethal in homozygotes, but heterozygotes have elevated triglycerides and impaired enzyme activity. J. Biol. Chem. 270, 12518-25 (1995).
46. Weinstock, P. H. et al. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J. Clin. Invest. 96, 2555-68 (1995).
47. Merkel, M. et al. Lipoprotein lipase expression exclusively in liver. A mouse model for metabolism in the neonatal period and during cachexia. J. Clin. Invest. 102, 893-901 (1998).
48. Babaev, V. R. et al. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J. Clin. Invest. 103, 1697-705 (1999).
49. Van Eck, M., Zimmermann, R., Groot, P. H., Zechner, R. & Van Berkel, T. J. Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, E53-62 (2000).
50. Bartolomé, N., Arteta, B., Martínez, M. J., Chico, Y. & Ochoa, B. Kupffer cell products and interleukin 1beta directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes. Innate Immun. 14, 255-66 (2008).
51. Ruan, H. et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 51, 3176-88 (2002).
52. Von Der Thüsen, J. H. et al. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/-mice. FASEB J. 15, 2730-2 (2001).
53. Mallat, Z. et al. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85, e17-24 (1999).
54. Potteaux, S. et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 24, 1474-8 (2004).
55. Fang, S.-M. et al. Allogeneic bone marrow mesenchymal stem cells transplantation for stabilizing and repairing of atherosclerotic ruptured plaque. Thromb. Res. 131, e253-7 (2013).
56. Lin, Y.-L., Yet, S.-F., Hsu, Y.-T., Wang, G.-J. & Hung, S.-C. Mesenchymal Stem Cells Ameliorate Atherosclerotic Lesions via Restoring Endothelial Function. Stem Cells Transl. Med. 4, 44-55 (2014).
57. Ito, M. et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175-82 (2002).
58. Shultz, L. D. et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477-89 (2005).
59. Van den Maagdenberg, A. M. et al. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J. Biol. Chem. 268, 10540-5 (1993).